This story originally ran on March 18.

OriGene Technologies this week announced that it has raised $16 million in its completed Series B financing round.

The proceeds will be used to continue building the company's TrueMab monoclonal antibody collection. In a statement, OriGene said that it aims to build a monoclonal antibody collection that will cover the entire human genome of about 20,000 genes or most of the human proteome.

"The funding will propel us closer to meeting our goal," Wei-Wu He, OriGene's chairman and CEO, said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.